Effects of Weekly Administrations of Alendronate + Clodronate on Young Mouse Tibia: Localized Action at the Proximal Growth Plate

Calcified Tissue International

Volumn 74, Issue 1, 2004, Pages 115-121

  Monma, Y ^a   Funayama, H ^a   Mayanagi, H ^a   Endo, Y ^a  

^a TOHOKU UNIVERSITY   (Japan)

Author keywords

Alendronate; Bisphosphonates; Bone resorption; Clodronate; Growth plate; Tibia

Indexed keywords

ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; CLODRONIC ACID;

ANIMAL EXPERIMENT; ARTICLE; BONE DENSITY; CONTROLLED STUDY; DRUG DOSE REGIMEN; DRUG EFFECT; GROWTH PLATE; INFLAMMATION; MALE; MOUSE; NONHUMAN; OSTEOLYSIS; PHYSICAL CHEMISTRY; PRIORITY JOURNAL; RADIOGRAPHY; TIBIA;

ALENDRONATE; ANIMALS; ANTI-INFLAMMATORY AGENTS; CALCIUM; CLODRONIC ACID; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; GROWTH PLATE; MALE; MICE; MICE, INBRED BALB C; TIBIA;

EID: 0842305688     PISSN: 0171967X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00223-002-2156-5     Document Type: Article

References (34)

1. Rodan GA, Fleisch HA (1996) Bisphosphonates: mechanism of action. J Clin Invest 97:2692-2696
2. Bonjour JP, Rizzoli R, Ammann P, Chevalley T (1994) Bisphosphonates in clinical medicine. In: Heershe NM, Kanis JK (Eds.) Bone and Mineral Research, vol 8. Elsevier Science BV, Amsterdam, pp 205-264
3. Geddes AD, D'Souza SM, Ebentino FH, Kenneth JI (1994) Bisphosphonates: structure-activity relationships and therapeutic implications. In: Heershe NM, Kanis JK (Eds.) Bone and Mineral Research, vol 8. Elsevier Science BV, Amsterdam, pp 265-306
4. Glorieux FH, Bishop NJ, Plotkin H, Chabot G, Lanoue G, Travers R (1998) Cyclic administration of pamidronate in children with severe osteogenesis imperfecta. N Engl J Med 339:947-952
5. Adami S, Bhalla AK, Dorizzi R, Montesani F, Rosini S, Salvagno G, Lo Cascio V (1987) The acute phase response after bisphosphonate administration. Calcif Tissue Int 41:326-331
6. Sauty A, Pecherstorfer M, Zimmer-Roth I, Fioroni P, Juillerat L, Markert M, Ludwig H, Leuenberger P, Burckhardt P, Thiébaud D (1996) Interleukin-6 and tumor necrosis factor α levels after bisphosphonates treatment in vitro and in patients with malignancy. Bone 18:133-139
7. Thiébaud D, Sauty A, Burckhardt P, Leuenberger P, Sitzler L, Green JR, Kandra A, Zieschang J, Ibarra de Palacios P (1997) An in vitro and in vivo study of cytokines in the acute-phase response associated with bisphosphonates. Calcif Tissue Int 61:386-392
8. Siris E (1993) Bisphosphonates and iritis. Lancet ii:436-437
9. Macarol V, Frauenfelder FT (1994) Pamidronate disodium and possible ocular adverse drug reactions. Am J Ophthamol 118:220-224
10. Fleisch HA (1997) Bisphosphonates: preclinical aspects and use in osteoporosis. Anal Med 29:56-62
11. Mönkkönen J, Koponen HM, Ylitalo P (1989) Comparison of the distribution of three bisphosphonates in mice. Pharmacol Toxicol 65:294-298
12. Endo Y, Nakamura N, Kikuchi T, Shinoda H, Takeda K, Nitta Y, Kumagai K (1993) Aminoalkylbisphosphonates, potent inhibitors of bone resorption, induce a prolonged stimulation of histamine synthesis and increase macrophages, granulocytes, and osteoclasts in vivo. Calcif Tissue Int 52:248-254
13. Nakamura M, Ando T, Masataka A, Kumagai K, Endo Y (1996) Contrast between effects of aminobisphosphonates and non-aminobisphosphonates on collagen-induced arthritis in mice. Br J Pharmacol 119:205-212
14. Sugawara S, Shibazaki M, Takada H, Kosugi K, Endo Y (1998) Contrasting effects of an aminobisphosphonate, a potent inhibitor of bone resorption, on lipopolysaccharide-induced production of interleukin-1 and tumour necrosis factor α in mice. Br J Pharmacol 125:735-740
15. Funayama H, Mayanagi H, Takada H, Endo Y (2000) Elevation of histidine decarboxylase activity in the mandible of mice by Prevotella intermedia lipopolysaccharide and its augmentation by an aminobisphosphonate. Arch Oral Biol 45:787-795
16. Yamaguchi K, Motegi K, Iwakura Y, Endo Y (2000) Involvement of interleukin-1 in the inflammatory actions of aminobisphosphonates in mice. Br J Pharmacol 130:1646-1654
17. Endo Y, Shibazaki M, Nakamura M, Kosugi H (1999) Inhibition of inflammatory actions of aminobisphosphonates by dichloromethylene bisphosphonate, a non-aminobisphosphonate. Br J Pharmacol 126:903-910
18. Kasting GB, Francis MD (1992) Retention of etidronate in human, dog, and rat. J Bone Miner Res 7:513-522
19. Devogelaer JP, Malghem J, Maldague B, Nagant de Deuxchaisnes D (1987) Radiological manifestation of bisphosphonate treatment with APD in a child suffering from osteogenesis imperfecta. Skeletal Radiol 16:360-363
20. Sato M, Grasser W, Endo N, Akins R, Simmons H, Thompson DD, Golub E, Rodan GA (1991) Bisphosphonate action: alendronate localization in rat bone and effects on osteoclast ultrastructure. J din Invest 88:2095-2105
21. Amin D, Cornell SA, Gustafson SK, Needle SJ, Ullrich JW, Bilder GE, Perrone MH (1992) Bisphosphonates used for the treatment of bone disorders inhibit squalene synthase and cholesterol biosynthesis. J Lipid Res 33:1657-1663
22. Amin D, Cornell SA, Perrone MH, Bilder GE (1996) 1-Hydroxy-3-(methylpentylamino)-propylidene-1,1-bisphosphonic acid as a potent inhibitor of squalene synthase. Drug Res 46:759-762
23. Fisher JE, Rogers MJ, Halasy JM, et al. (1999) Alendronate mechanism of action: geranylgeraniol, an intermediate in the mevalonate pathway, prevents inhibition of osteoclasts formation, bone resorption, and kinase activation in vitro. Proc Natl Acad Sci USA 96:133-138
24. Van Beek E, Löwik C, Van Der Pluijm G, Papapoulos S (1999) The role of geranylgeranylation in bone resorption and its suppression by bisphosphonates in fetal bone explants in vitro: a clue to the mechanism of action of nitrogen-containing bisphosphonates. J Bone Miner Res 14:722-729
25. Van Beek E, Pieterman E, Cohen L, Löwik C, Papapoulos S (1999) Nitrogen-containing bisphosphonates inhibit isopentenyl pyrophosphate isomerase/farnesyl pyrophosphate synthase activity with relative potencies corresponding to their antiresorptive potencies in vitro and in vivo. Biochem Biophys Res Commun 255:491-494
26. Van Beek E, Pieterman E, Cohen L, Löwik C, Papapoulos S (1999) Farnesyl pyrophosphate synthase is the molecular target of nitrogen-containing bisphosphonates. Biochem Biophys Res Commun 264:108-111
27. Martin MB, Arnold W, Heath HT, Urbina JA, Oldfield E (1999) Nitrogen-containing bisphosphonates as carbocation transition state analogs for isoprenoid biosynthesis. Biochem Biophys Res Commun 263:754-758
28. Keller K, Fliesler SJ (1999) Mechanism of aminobisphosphonate action: characterization of alendronate inhibition of isoprenoid pathway. Biochem Biophys Res Commun 266:560-563
29. Frith JC, Mönkkönen J, Blackburn GM, Russel RG, Rogers MJ (1997) Clodronate and liposome-encapsulated clodronate are metabolized to a toxic ATP analog, adenosine 5′-(beta, gamma-dichloromethylene) triphosphate, by mammalian cells in vitro. J Bone Miner Res 12:1358-1367
30. Auriola S, Frith JC, Rogers MJ, Koivuniemi A, Mönkkönen J (1997) Identification of adenine nucleotide-containing metabolites of bisphosphonate drugs using ion-pair liquid chromatography-electrospray mass spectrometry. J Chromatogr B 704:187-195
31. Halasy-Nagy JM, Rodan GA, Reszka AA (2001) Inhibition of bone resorption by alendronate and risedronate does not require osteoclast apoptosis. Bone 29:553-559
32. Suri S, Mönkkonen J, Taskinen M, Pesonen J, Blank MA, Phipps RJ, Rogers MJ (2001) Nitrogen-containing bisphosphonates induce apoptosis of Cao-2 cells in vitro by inhibiting the mevalonate pathway: a model of bisphosphonate-induced gastrointestinal toxicity. Bone 29:336-343
33. Reszka AA, Halasy-Nagy J, Rodan GA (2001) Nitrogen-bisphosphonate block retinoblastoma phosphorylation and cell growth by inhibiting the cholesterol biosynthetic pathway in keratinocyte model for esophageal irritation. Mol Pharmacol 59:193-202
34. Ayada K, Oguri S, Yamaguchi K, Kumagai K, Endo Y (2003) Elevation of histidine decarboxylase activity in the stomach of mice by ulcerogenic drugs. Eur J Pharmacol 460:63-69